文献速递消化系统肿瘤

阿替利珠单抗抗药抗体高水平与肝细胞癌患者临床结局及T细胞应答的关联

Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma.
PubMed 文献 · JAMA Oncol · 2022-01-01

这项队列研究前瞻性纳入174例接受一线阿替利珠单抗/贝伐珠单抗治疗的晚期肝细胞癌患者,最终分析132例,发现第2周期第1天(C2D1)抗药抗体(ADA)高水平(≥1000 ng/mL)与较低的缓解率、较差的无进展生存期和总生存期相关,并与阿替利珠单抗血药浓度降低及CD8阳性T细胞功能受损相关。

要点

  • C2D1 ADA≥1000 ng/mL者占17.4%,其缓解率在发现队列为34% vs 11%、验证队列为29% vs 7%。
  • 高ADA水平与更差的无进展生存期和总生存期相关,多变量校正后关联仍存在。
  • 高ADA水平者阿替利珠单抗血药浓度降低,CD8阳性T细胞增殖及干扰素-γ和肿瘤坏死因子-α分泌减少。

核心结论

  • C2D1时ADA水平高度升高可能与接受阿替利珠单抗/贝伐珠单抗治疗的晚期肝细胞癌患者较差的临床结局相关。
  • 高ADA水平可能降低阿替利珠单抗暴露并减弱该药的抗癌疗效。

研究设计与样本

  • 这是一项前瞻性队列研究,纳入174例接受一线阿替利珠单抗/贝伐珠单抗治疗的晚期肝细胞癌患者(发现队列61例来自1个中心,验证队列113例来自4个中心)。
  • 排除样本不足、失访或撤回知情同意者后,最终分析132例(发现队列50例,41例[82.0%]为男性,中位年龄[IQR]61[55-70]岁;验证队列82例,70例[85.4%]为男性,中位年龄[IQR]61[53-68]岁)。
  • 采用竞争性酶联免疫吸附试验分析治疗前及3周时(第2周期第1天[C2D1])的血清ADA水平,并进行血清学和流式细胞术分析。

主要发现

  • C2D1时鉴定出强ADA反应(≥1000 ng/mL)者23例(17.4%)。
  • 疾病进展患者C2D1时ADA水平(中位[IQR]65.2[0-520.4] ng/mL)高于缓解者(中位[IQR]0[0-117.5] ng/mL)。
  • 在发现队列和验证队列中,C2D1时高ADA水平者与低ADA水平者相比缓解率降低(发现队列:34% vs 11%;验证队列:29% vs 7%)。
  • 高ADA水平者与低ADA水平者相比无进展生存期更差(发现队列:HR 2.84;95%CI 1.31-6.13;P=.005;验证队列:HR 2.52;95%CI 1.27-5.01;P=.006),总生存期也更差(发现队列:HR 3.30;95%CI 1.43-7.64;P=.003;验证队列:HR 5.81;95%CI 2.70-12.50;P=.001)。
  • 多变量Cox回归中,校正多种混杂因素后高ADA水平的临床意义仍存在,且在≥1000 ng/mL时最显著。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Administration of atezolizumab could be immunogenic and induce undesirable antidrug antibody (ADA) responses. This may interfere with atezolizumab-mediated actions, affecting drug clearance and serum concentration or inducing antibody neutralization. OBJECTIVE: To determine the clinical and immunological associations of highly elevated ADA levels with clinical outcomes after atezolizumab/bevacizumab (Atezo/Bev) treatment in patients with advanced hepatocellular carcinoma (HCC). DESIGN, SETTING, AND PARTICIPANTS: This cohort study prospectively enrolled 174 patients with advanced HCC treated with first-line Atezo/Bev (discovery cohort: 61 patients from 1 center; validation cohort: 113 patients from 4 centers). EXPOSURES: Serum ADA levels at pretreatment and 3 weeks (cycle 2 day 1 [C2D1]) were analyzed using competitive enzyme-linked immunosorbent assays. In addition, samples were subjected to serological and flow cytometric analyses. MAIN OUTCOMES AND MEASURES: Overall, ADA positivity was associated with treatment outcomes and T-cell functions. RESULTS: After excluding patients with inadequate samples, follow-up loss, or consent withdrawal, 132 patients (discovery cohort: 50 patients; 41 [82.0%] men; median age [IQR], 61 [55-70] years; validation cohort: 82 patients; 70 [85.4%] men; median age [IQR], 61 [53-68] years) were analyzed, and robust ADA (≥1000 ng/mL) responses at C2D1 were identified in 23 (17.4%) of the patients. Patients with progressive disease exhibited higher ADA levels (median [IQR], 65.2 [0-520.4] ng/mL) at C2D1 than in responders (median [IQR], 0 [0-117.5] ng/mL). In both discovery and validation cohorts, patients with high ADA levels at C2D1 were associated with a reduced response rate (discovery cohort: 34% vs 11%; validation cohort: 29% vs. 7%) and worse progression-free survival (discovery cohort: hazard ratio [HR], 2.84; 95% CI, 1.31-6.13; P = .005; validation cohort: HR, 2.52; 95% CI, 1.27-5.01; P = .006) and overall survival (discovery cohort: HR, 3.30; 95% CI, 1.43-7.64; P = .003; validation cohort: HR, 5.81, 95% CI, 2.70-12.50; P = .001) with Atezo/Bev compared with those with low ADA levels. In multivariable Cox regression, the clinical implication of high ADA levels persisted even after adjusting for various confounding factors and was most significant at 1000 ng/mL or greater. Compared with patients with low ADA levels, patients with high ADA levels exhibited reduced serum atezolizumab concentrations, impaired CD8-positive T-cell proliferation, and had decreased interferon-γ and tumor necrosis factor-α from CD8-positive T cells compared with patients with low ADA levels. CONCLUSIONS AND RELEVANCE: This cohort study found that highly elevated ADA levels at C2D1 may be associated with poor clinical outcomes in patients with advanced HCC treated with Atezo/Bev. High ADA levels may reduce atezolizumab exposure and attenuate the anticancer efficacy of the drug.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Kim C, Yang H, Kim I, et al. Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma. JAMA Oncol. 2022. PMID: 36264560. doi:10.1001/jamaoncol.2022.4733

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。